Shareholders in ProQR Therapeutics N.V. (NASDAQ:PRQR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that ProQR Therapeutics will make substantially more sales than they'd previously expected.

Our free stock report includes 3 warning signs investors should be aware of before investing in ProQR Therapeutics. Read for free now.

After the upgrade, the consensus from ProQR Therapeutics' seven analysts is for revenues of €19m in 2025, which would reflect a measurable 5.4% decline in sales compared to the last year of performance. Per-share losses are expected to explode, reaching €0.38 per share. Yet before this consensus update, the analysts had been forecasting revenues of €17m and losses of €0.40 per share in 2025. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrades to both revenue and loss per share forecasts for this year.

Check out our latest analysis for ProQR Therapeutics

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 7.1% by the end of 2025. This indicates a significant reduction from annual growth of 57% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - ProQR Therapeutics is expected to lag the wider industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting ProQR Therapeutics is moving incrementally towards profitability. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at ProQR Therapeutics.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple ProQR Therapeutics analysts - going out to 2027, and you can see them free on our platform here.